Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Fox Corp Class A (FOXA) Price & Performance

Enveric Biosciences IncTrade
Fox Corp Class ATrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Fox Corp Class A — how do they compare? Enveric Biosciences Inc trades at $1.36 (market cap $5.32M), while Fox Corp Class A trades at $56.49 (market cap $22.28B). The key difference: Fox Corp Class A is far larger — about 4188× Enveric Biosciences Inc's market cap, and Fox Corp Class A pays a 1% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

ENVBFOXA
Market Cap
$5.32M$22.28B
Sector
HealthMedia
52-Week High
$17.40$76.11
52-Week Low
$1.28$48.79
Enterprise Value
$408.82K$26.25B
Dividend Yield
1%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.

Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.

Fox Corp Class A

Fox Corporation (FOXA) trades at $55.94, up 1.95% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 14.73 and net income margin of 10.56%, supported by $3.32B in operating cash flow for 2025. Recent news highlights the strategic $22B Roku acquisition, positioning Fox in the competitive streaming landscape.

The outlook is mixed: analyst consensus targets $67.80 (21% upside) with equal buy/hold ratings, but technicals and 2026 cash flow projections signal caution. Key risks include integration challenges from the Roku deal and advertising market volatility. The stock presents a value opportunity if execution risks are managed.

Returns comparison

Trailing returns across standard periods

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Fox Corp Class A

Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.

Read more on FOXA